In situ gene therapy for prostate cancer

Current Gene Therapy

Volumn 5, Issue 1, 2005, Pages 111-119

  Satoh, Takefumi ^a   Irie, Akira ^a   Egawa, Shin ^a   Baba, Shiro ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Gene therapy; Immunomodulatory approaches; Prostate cancer

Indexed keywords

B7 ANTIGEN; BRCA1 PROTEIN; CD4 ANTIGEN; CD8 ANTIGEN; CD86 ANTIGEN; CELL ADHESION MOLECULE; CREATININE; DNA; FLUCYTOSINE; GAMMA INTERFERON; GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 2; NITRIC OXIDE SYNTHASE; ONCOLYTIC VIRUS; OSTEOCALCIN; PHOSPHOTRANSFERASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL 2; PROTEIN P16; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN; THYMIDINE KINASE; UNINDEXED DRUG; VALACICLOVIR; VIRUS DNA;

ADENOVIRUS; ADVANCED CANCER; ANEMIA; ANTINEOPLASTIC ACTIVITY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SUBSTITUTION; GENE THERAPY; GENE TRANSFER; GEOGRAPHY; HEMATOLOGIC DISEASE; HERPES SIMPLEX VIRUS; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; INJECTION PAIN; INJECTION SITE REACTION; LIVER DYSFUNCTION; MALE; MEDICAL DECISION MAKING; METASTASIS POTENTIAL; NONVIRAL GENE DELIVERY SYSTEM; OUTCOMES RESEARCH; OVARY CANCER; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SUICIDE GENE THERAPY; THROMBOCYTOPENIA; VIRAL GENE DELIVERY SYSTEM;

EID: 13844276209     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/1566523052997523     Document Type: Review

References (59)

1. Aaltomaa, S., Lipponen, P., Eskelinen, M., Ala-Opas, M., Kosma, V.M. (1999) Prognostic value and expression of p21(waf1/cip1) protein in prostate cancer. Prostate, 39: 8-15.
2. Allay, J.A., Steiner, M.S., Zhang, Y., Reed, C.P., Cockroft, J., Lu, Y. (2000) Adenovirus p16 gene therapy for prostate cancer. World J. Urol., 18: 111-120.
3. Ayala, G., Wheeler, T.M., Shalev, M., Thompson, T.C., Miles, B., Aguilar-Cordova, E., Chakraborty, S. and Kadmon, D. (2000) Cytopathic effect of in situ gene therapy in prostate cancer. Hum. Pathol., 31: 866-870.
4. Belldegrun, A., Tso, C.L., Zisman, A., Naitoh, J., Said, J., Pantuck, A.J., Hinkel, A., deKernion, J. and Figlin, R. (2001) Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology. Hum. Gene Ther., 12: 883-892.
5. Chen, L., McGowan, P., Ashe, S., Johnston, J.V., Hellstrom, I., Hellstrom, K.E. (1994) B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum. Cancer Res., 54: 5420-5423.
6. Chen, Y., DeWeese, T., Dilley, J., Zhang, Y., Li. Y., Ramesh, N., Lee, J., Pennathur-Das R., Radzyminski, J., Wypych, J., Brignetti, D., Scott S., Stephens, J., Karpf, D.B., Henderson, D.R., Yu, D.C. (2001) CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. Cancer Res., 61:5453-5460.
7. Cosman, D., Kumaki, S., Ahdieh, M., Eisenman, J., Grabstein, K.H., Paxton, R., DuBose, R., Friend, D., Park, L.S., Anderson, D. (1995) Interleukin 15 and its receptor. Ciba Found. Symp., 195 221-229; discussion 229-233.
8. DeWeese, T.L., van der, Poel, H., Li, S., Mikhak, B., Drew, R., Goemann, M., Hamper, U., DeJong, R., Detorie, N., Rodriguez, R., Haulk, T., DeMarzo, A.M., Piantadosi, S., Yu, D.C., Chen, Y., Henderson, D.R., Carducci, M.A., Nelson, W.G., Simons, J.W. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res., 61:7464-7472.
9. Eastham, J.A., Hall, S.J., Sehgal, I., Wang, J., Timme, T.L., Yang, G., Connell-Crowley, L., Elledge, S.J., Zhang, W.W., Harper, J.W. (1995) In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res., 55: 5151-5155.
10. Epstein, J.I., Carmichael, M.J., Partin, A.W. and Walsh, P.C. (1994) Small high grade adenocarcinoma of the prostate in radical prostatectomy specimens performed for nonpalpable disease: pathogenetic and clinical implications. J. Urol., 151: 1587-1592.
11. Freytag, S.O., Khil, M., Stricker, U., Peabody, J., Menon, M., DePeralta-Venturina, M., Nafziger, D., Pegg, J., Paielli, D., Brown, S., Barton, K., Lu, M., Aguilar-Cordova, E., and Kim, J.H. (2002) Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res, 62: 4968-4976.
12. Freytag, S.O., Rogulski, K.R., Paielli, D.L., Gilbert, J.D. and Kim, J.H. (1998) A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum. Gene Ther., 9: 1323-1333.
13. Gately, M.K., Renzetti, L.M., Magram, J., Stern, A.S., Adorini, L., and Gubler, U., Presky, D.H. (1998) The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Ann. Rev. Immunol., 16: 495-521.
14. Goto, Y., Ohori, M., Arakawa, A., Kattan, M.W., Wheeler, T.M. and Scardino, P.T. (1996) Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J. Urol., 156: 1059-1063.
15. Herman, J.R., Adler, H.L., Aguilar-Cordova, E., Rojas-Martinez, A., Woo, S., Timme, T.L., Wheeler, T.M., Thompson, T.C. and Scardino, P.T. (1999) In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum. Gene Ther., 10: 1239-1249.
16. Jarrard, D.F., Bova, G.S., Ewing, C.M., Pin, S.S., Nguyen, S.H., Baylin, S.B., Cairns, P., Sidransky, D., Herman, J.G., Isaacs, W.B. (1997) Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer. Genes Chromosomes Cancer, 19: 90-96.
17. Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E. and Thun, M.J. (2003) Cancer statistics. CA Cancer J. Clin., 53: 5-26.
18. Kang, W.K., Park, C., Yoon, H.L., Kim, W.S., Yoon, S.S., Lee, M.H., Park, K., Kim, K., Jeong, H.S., Kim, J.A., Nam, S.J., Yang, J.H., Son, Y.I., Baek, C.H., Han, J., Ree, H.J., Lee, E.S., Kim, S.H., Kim, D.W., Ahn, Y.C., Huh, S.J., Choe, Y.H., Lee, J.H., Park, M.H., Kong, G.S., Park, E.Y., Kang, Y.K., Bang, Y.J., Paik, N.S., Lee, S.N., Kim, S.H., Kim, S., Robbins, P.D., Tahara, H., Lotze, M.T. and Park, C.H. (2001) Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study. Hum. Gene Ther., 12: 671-684.
19. Kitagawa, T., Tsukuma, H., Ajiki, K. and Oshima, A. (1999) Prediction of cancer incidence in Japan, Shinohara Shuppan, Tokyo.
20. Kubo, H., Gardner, T.A., Wada, Y., Koeneman, K.S., Gotoh, A., Yang, L., Kao, C., Lim, S.D., Amin, M.B., Yang, H., Black, M.E., Matsubara, S., Nakagawa, M., Gillenwater, J.Y., Zhau, H.E. and Chung, L.W. (2003) Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum. Gene Ther., 14: 227-241.
21. Lebel-Binay, S., Berger, A., Zinzindohoue, F., Cugnenc, P., Thiounn, N., Fridman, W.H., Pages, F. (2000) Interleukin-18: biological properties and clinical implications. Eur. Cytokine Netw., 11 15-26.
22. Levine, A.J. (1997) p53, the cellular gatekeeper for growth and division. Cell, 88: 323-331.
23. Lin, S.H., Pu, Y.S. (1999) Function and therapeutic implication of C-CAM cell-adhesion molecule in prostate cancer. Semin. Oncol., 26: 227-233.
24. Lin, S.H., Pu, Y.S., Luo, W., Wang, Y., Logothetis, C.J. (1999) Schedule-dependence of C-CAM1 adenovirus gene therapy in a prostate cancer model. Anticancer Res., 19: 337-340.
25. McDonnell, T.J., Troncoso, P., Brisbay, S.M., Logothetis, C., Chung, L.W., Hsieh, J.T., Tu, S.M., Campbell, M.L. (1992) Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res., 52: 6940-6944.
26. Matsubara, S., Wada, Y., Gardner, T.A., Egawa, M., Park, M.S., Hsieh, C.L., Zhau, H.E., Kao, C., Kamidono, S., Gillenwater, J.Y. and Chung, L.W. (2001) A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. Cancer Res., 61: 6012-6019.
27. Merritt, J.A., Roth, J.A. and Logothetis, C.J. (2001) Clinical evaluation of adenoviral-mediated p53 gene transfer: review of INGN 201 studies. Semin. Oncol., 28: 105-114.
28. Mineta, T., Rabkin, S.D., Yazaki, T., Hunter, W.D., Martuza, R.L. (1995) Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med, 9 938-943.
29. Miles, B.J., Shalev, M., Aguilar-Cordova, E., Timme, T.L., Lee, H.M., Yang, G., Adler, H.L., Kemen, K., Pramudji, C.K., Satoh, T., Gdor, Y., Ren, C., Ayala, G., Wheeler, T.M., Butler, E.B., Kadmon, D. and Thompson, T.C. (2001) Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum. Gene Ther., 12: 1955-1967.
30. Nasu, Y., Bangma, C.H., Hull, G.W., Lee, H.M., Hu, J., Wang, J., McCurdy, M.A., Shimura, S., Yang, G., Timme, T.L. and Thompson, T.C. (1999) Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model. Gene Ther., 6: 338-349.
31. Nasu, Y., Bangma, C.H., Hull, G.W., Yang, G., Wang, J., Shimura, S., McCurdy, M.A., Ebara, S., Lee, H.M., Timme, T.L. and Thompson, T.C. (2001) Combination gene therapy with adenoviral vector-mediated HSV-tk+GCV and IL-12 in an orthotopic mouse model for prostate cancer. Prostate Cancer Prostatic Dis., 4: 44-55.
32. Nasu, Y., Kusaka, N., Saika, T., Tsushima, T. and Kumon, H. (2000) Suicide gene therapy for urogenital cancer: current outcome and prospects. Mol. Urol., 4: 67-71.
33. Noguchi, M., Stamey, T.A., McNeal, J.E. and Yemoto, C.M. (2001) Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer. J. Urol., 166: 104-109; discussion 109-110.
34. Ohori, M, Wheeler, T.M., Kattan, M.W., Goto, Y. and Scardino, P.T. (1995) Prognostic significance of positive surgical margins in radical prostatectomy specimens. J. Urol., 154: 1818-1824.
35. Ren, C., Li, L., Goltsov, A.A., Timme, T.L., Tahir, S.A., Wang, J., Garza, L., Chinault, A.C. and Thompson, T.C. (2002) mRTVP-1, a novel p53 target gene with proapoptotic activities. Mol. Cell Biol. 22: 3345-3357.
36. Rodriguez, R., Schuur, E.R., Lim, H.Y., Henderson, G.A., Simons, J.W., Henderson, D.R. (1997) Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 57:2559-2563.
37. Rogulski, K.R., Wing, M.S., Paielli, D.L., Gilbert, J.D., Kim, J.H. and Freytag, S.O. (2000) Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization. Hum. Gene Ther. 11: 67-76.
38. Rojas-Martinez, A., Esteban-Maria, J., Gonzalez-Guerrero, J.F., Garza-Guajardo, R., Delgado-Enciso, I., Flores-Gutierrez, J.P., Aguilar, L., Butler, E.B., Kadmon, D., Barrera-Saldana, H.A. and Aguilar-Cordova, E. (2003) Pre-prostatectomy Adv-tk/prodrug gene therapy prostate cancer clinical trial in Mexico: Analysis of vector distribution and antitumor effects. Mol. Ther., 7: 283.
39. Rosen, E.M., Fan, S., Goldberg, I.D. (2001) BRCA1 and prostate cancer. Cancer Invest., 19: 396-412.
40. Sakr, W.A., Macoska, J.A., Benson, P., Grignon, D.J., Wolman, S.R., Pontes, J.E. and Crissman, J.D. (1994) Allelic loss in locally metastatic, multisampled prostate cancer. Cancer Res., 54: 3273-3277.
41. Salomons, G.S., Brady, H.J., Verwijs-Janssen, M., Van Den Berg, J.D., Hart, A.A., Van Den Berg, H., Behrendt, H., Hahlen, K., Smets, L.A. (1997) The Bax alpha:Bcl-2 ratio modulates the response to dexamethasone in leukaemic cells and is highly variable in childhood acute leukaemia. Int. J. Cancer, 71:959-965.
42. Satoh, T., Timme, T.L., Saika, T., Ebara, S., Yang, G., Wang, J., Ren, C., Kusaka, N., Mouraviev, V., and Thompson, T.C. (2003) Adenoviral vector-mediated mRTVP-1 gene therapy for prostate cancer. Hum. Gene Ther., 14: 91-101.
43. Scott, P. (1993) IL-12: initiation cytokine for cell-mediated immunity. Science, 260: 496-497.
44. Serrano, M., Hannon, G.J., Beach, D. (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature, 366: 704-707.
45. Shalev, M., Kadmon, D., Teh, B.S., Butler, E.B., Aguilar-Cordova, E., Thompson, T.C., Herman, J.R., Adler, H.L., Scardino, P.T. and Miles, B.J. (2000) Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer. J. Urol., 163: 1747-1750.
46. Stamey, T.A., Freiha, F.S., McNeal, J.E., Redwine, E.A., Whittemore, A.S. and Schmid, H.P. (1993) Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer, 71: 933-938.
47. Steiner, M.S., Wang, Y., Zhang, Y., Zhang, X., Lu, Y. (2000) p16/MTS1/INK4A suppresses prostate cancer by both pRb dependent and independent pathways. Oncogene, 19:1297-1306.
48. Suzuki, K., Nakazato, H., Matsui, H., Hasumi, M., Shibata, Y., Ito, K., Fukabori, Y., Kurokawa, K., Yamanaka, H. (2001) NK cell-mediated anti-tumor immune response to human prostate cancer cell, PC-3: immunogene therapy using a highly secretable form of interleukin-15 gene transfer. J. Leukoc. Biol., 69: 531-537.
49. Syrigos, K.N., Harrington, K.J., Pignatelli, M. (1999) Role of adhesion molecules in bladder cancer: an important part of the jigsaw. Urology, 53: 428-434.
50. Tait, D.L., Obermiller, P.S., Hatmaker, A.R., Redlin-Frazier, S., Holt, J.T. (1999) Ovarian cancer BRCA1 gene therapy: Phase I and II trial differences in immune response and vector stability. Clin. Cancer Res., 5: 1708-1714.
51. Tamura, T., Nishi, T., Goto, T., Takeshima, H., Ushio, Y., Sakata, T. (2003) Combination of IL-12 and IL-18 of electro-gene therapy synergistically inhibits tumor growth. Anticancer Res., 23: 1173-1179.
52. Teh, B.S., Aguilar-Cordova, E., Kernen, K., Chou, C.C., Shalev, M., Vlachaki, M.T., Miles, B., Kadmon, D., Mai, W.Y., Caillouet, J., Davis, M., Ayala, G., Wheeler, T., Brady, J., Carpenter, L.S., Lu, H.H., Chiu, J.K., Woo, S.Y., Thompson, T.C., and Butler, E.B. (2001) Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer - a preliminary report. Int. J. Radiat. Oncol. Biol. Phys., 51: 605-613.
53. Thompson, T.C., Park, S.H., Timme, T.L., Ren, C., Eastham, J.A., Donehower, L.A., Bradley, A., Kadmon, D., and Yang, G. (1995) Loss of p53 function leads to metastasis in ras+myc-initiated mouse prostate cancer. Oncogene, 10: 869-879.
54. Thompson, T.C., Timme, T.L., and Shegal, I. (1996) The role of p53 in prostate cancer progression. In: Accomplishments in Cancer Research, eds. Fortner J. & Sharp, P. Lippincott-Raven, Philadelphia, pp280-289.
55. Tsujimoto, Y., Cossman, J., Jaffe, E., Croce, C.M. (1985) Involvement of the bcl-2 gene in human follicular lymphoma. Science 228:1440-1443.
56. Varghese, S., Rabkin, S.D. (2002) Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther. 12: 967-978.
57. Walker, J.R., McGeagh, K.G., Sundaresan, P., Jorgensen, T.J., Rabkin, S.D., Martuza, R.L. (1999) Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Hum. Gene Ther., 13: 2237-2243.
58. Yazaki, T., Manz, H.J., Rabkin, S.D., Martuza, R.L. (1995) Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res., 55 4752-4756.
59. Zietman, A.L., Edelstein, R.A., Coen, J.J., Babayan, R.K., and Krane, R.J. (1994) Radical prostatectomy for adenocarcinoma of the prostate: the influence of preoperative and pathologic findings on biochemical disease-free outcome. Urology, 43: 828-833.